Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Rhumbline Advisers trimmed its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 20.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,531 shares of the biopharmaceutical company’s stock after selling 14,964 shares during the quarter. Rhumbline Advisers owned 0.09% of Regulus Therapeutics worth $94,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Creative Planning purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $26,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $46,000. JPMorgan Chase & Co. raised its position in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 52,059 shares in the last quarter. Barclays PLC raised its position in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Regulus Therapeutics during the 3rd quarter worth about $204,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Trading Up 3.1 %

NASDAQ:RGLS opened at $1.33 on Tuesday. Regulus Therapeutics Inc. has a 12-month low of $0.83 and a 12-month high of $3.79. The firm has a market cap of $87.12 million, a P/E ratio of -1.24 and a beta of 1.42. The stock’s 50 day simple moving average is $1.29 and its 200-day simple moving average is $1.47.

Insiders Place Their Bets

In other news, CFO Crispina Calsada sold 38,716 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at $63,713.16. This represents a 43.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joseph P. Hagan purchased 50,000 shares of Regulus Therapeutics stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $1.09 per share, with a total value of $54,500.00. Following the acquisition, the chief executive officer now directly owns 260,808 shares of the company’s stock, valued at $284,280.72. The trade was a 23.72 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 223,998 shares of company stock worth $282,237. 4.35% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Regulus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.